Entrectinib
Brand names: Rozlytrek · Active ingredient: Entrectinib
In short: ROZLYTREK is indicated for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. ROZLYTREK is indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: have a neurotro
What is Entrectinib used for?
ROZLYTREK is indicated for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.
ROZLYTREK is indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that:
have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation,
are metastatic or where surgical resection is likely to result in severe morbidity, and
have progressed following treatment or have no satisfactory alternative therapy.
This indication is approved under accelerated approval based on tumor response rate and durability of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Entrectinib dosage
Select patients for the treatment of metastatic NSCLC with ROZLYTREK based on the presence of ROS1 rearrangement(s) in tumor or plasma specimens . Testing using plasma specimens is only appropriate for patients for whom tumor tissue is not available for testing.Information on FDA-approved tests for the detection of ROS1 rearrangement(s) in NSCLC is available at http://www.fda.gov/CompanionDiagnostics.
Select patients for treatment of locally advanced or metastatic solid tumors with ROZLYTREK based on the presence of a NTRK gene fusion in tumor or plasma specimens . Testing using plasma specimens is only appropriate for patients for whom tumor tissue is not available for testing.Information on FDA-approved tests for the detection of NTRK gene fusion(s) in solid tumors is available at http://www.fda.gov/CompanionDiagnostics.
Before initiating ROZLYTREK, evaluate:
Left ventricular ejection fraction (LVEF)
QRS and QTc intervals and electrolytes
Serum uric acid levels
The physician should prescribe the most appropriate dosage form of ROZLYTREK according to the dose required and patient needs.
ROZLYTREK is available in two dosage forms, and can be administered either as capsules swallowed whole, capsules made into an oral suspension (or for enteral tube administration) and as oral pellets swallowed with soft food.
ROZLYTREK Capsules 100 mg and 200 mg
Whole capsules: For patients who can swallow whole capsules and whose doses are multiples of 100 mg.
Capsules prepared as an oral suspension:
For patients who have difficulty or are unable to swallow capsules or who require enteral administration (e.g., gastric or nasogastric tube). .
For dose increments of 10 mg, only use capsules prepared as a suspension.
ROZLYTREK Oral Pellets 50 mg per packet
Pellets sprinkled on one or more spoonfuls of soft food:
For patients who have difficulty or are unable to swallow capsules but can swallow soft food and whose doses are multiples of 50 mg. .
Do not use pellets for preparation of suspension.
Do not attempt to use partial quantities of pellets from 50 mg pellet packets to prepare a dose.
Do not use the pellet formulation for enteral tube administration as the pellets may clog the tube.
Administer ROZLYTREK capsules, capsules prepared as a suspension, or pellets once daily, with or without food.
If a dose of ROZLYTREK is missed, make up that dose unless the next dose is due within 12 hours.
If vomiting occurs immediately after taking a dose of ROZLYTREK, repeat that dose.
The recommended dosage of ROZLYTREK is 600 mg orally once daily with or without food until disease progression or unacceptable toxicity.
The recommended dosages of ROZLYTREK for the treatment of adult and pediatric patients with NTRK Gene Fusion-Positive Solid Tumors are provided in Table 1. …
How to take Entrectinib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Congestive Heart Failure
Inform patients of the risks of CHF and advise patients to contact their healthcare provider immediately for any new or worsening signs or symptoms of CHF .
Ventricular Arrhythmias
Inform patients of the risks of QRS or QTc interval prolongation and Brugada syndrome, and advise them to report a history of Brugada syndrome, clinically significant arrhythmias, or heart failure and to contact their healthcare provider immediately for severe dizziness, syncope or palpitations .
Central Nervous System Effects
Advise patients to inform their healthcare provider if they experience new or worsening central nervous system symptoms. Instruct patients not to drive or operate hazardous machinery if they are experiencing CNS adverse reactions .
Skeletal Fractures
Inform patients that bone fractures have been reported in patients taking ROZLYTREK. Advise patients to report symptoms such as pain, changes in mobility, or deformity to their healthcare provider . …
Warnings & precautions
Do not take this medicine if: None.
Among the 355 patients who received ROZLYTREK across clinical trials, congestive heart failure (CHF) occurred in 3.4% of patients, including Grade 3 (2.3%) . In clinical trials, baseline cardiac function and routine cardiac monitoring other than electrocardiograms (ECGs) were not conducted and eligibility criteria excluded patients with symptomatic CHF, myocardial infarction, unstable angina, and coronary artery bypass graft within 3 months of study entry. Among the 12 patients with CHF, the median time to onset was 2 months (range: 11 days to 12 months). ROZLYTREK was interrupted in 6 of these patients (50%) and discontinued in 2 of these patients (17%). CHF resolved in 6 patients (50%) following interruption or discontinuation of ROZLYTREK and institution of appropriate medical management. In addition, myocarditis in the absence of CHF was documented in 0.3% of patients.
Assess left ventricular ejection fraction (LVEF) prior to initiation of ROZLYTREK. Monitor patients for clinical signs and symptoms of CHF, including shortness of breath and edema. For patients with myocarditis, with or without a decreased ejection fraction, MRI or cardiac biopsy may be required to make the diagnosis. For patients with new onset or worsening CHF, withhold ROZLYTREK, institute appropriate medical management, and reassess LVEF. Based on the severity of CHF or worsening LVEF, resume ROZLYTREK at a reduced dose upon recovery to baseline or permanently discontinue .
Among the 355 patients who received ROZLYTREK across the clinical trials, 3.1% of patients with at least one post-baseline ECG assessment experienced QTc interval prolongation of > 60 ms after starting ROZLYTREK and 0.6% had a QTc interval > 500 ms. …
Entrectinib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Congestive Heart Failure
Ventricular Arrhythmias
Central Nervous System Effects
Skeletal Fractures
Hepatotoxicity
Hyperuricemia
Vision Disorders
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Data in WARNINGS AND PRECAUTIONS and below reflect exposure to ROZLYTREK in 355 patients, including 172 (48%) patients exposed for 6 months or longer and 84 (24%) patients exposed for 1 year or longer. ROZLYTREK was studied in one dose-finding trial in adults [ALKA (n = 57)], one dose-finding and activity-estimating trial in adults [STARTRK-1 (n = 76)], one dose-finding and activity-estimating trial in pediatric and adult patients [STARTRK-NG (n = 16)], and one single arm, activity-estimating trial in adults [STARTRK-2 (n = 206)].
The population characteristics were: median age 55 years (range: 4 to 86 years); 5% (n = 17) were less than 18 years of age; 55% were female; and 66% were White, 23% were Asian, and 5% were Black; 3% were Hispanic/Latino. The most common tumors (≥ 5%) were lung (56%), sarcoma (8%), and colon (5%). ROS1 gene fusions were present in 42% and NTRK gene fusions were present in 20%. Most adults (75%) received ROZLYTREK 600 mg orally once daily. …
Drug interactions
Moderate and Strong CYP3A Inhibitors
Adults and Pediatric Patients 2 Years and Older
Coadministration of ROZLYTREK with a strong or moderate CYP3A inhibitor increases entrectinib plasma concentrations , which could increase the frequency or severity of adverse reactions. Avoid coadministration of strong or moderate CYP3A inhibitors with ROZLYTREK. If coadministration is unavoidable, reduce the ROZLYTREK dose .
Pediatric Patients less than 2 Years
Avoid coadministration of ROZLYTREK with moderate or strong CYP3A inhibitors .
Avoid grapefruit products during treatment with ROZLYTREK, as they contain inhibitors of CYP3A.
Moderate and Strong CYP3A Inducers
Coadministration of ROZLYTREK with a strong or moderate CYP3A inducer decreases entrectinib plasma concentrations , which may reduce ROZLYTREK efficacy. Avoid coadministration of strong and moderate CYP3A inducers with ROZLYTREK.
QRS prolongation, including Brugada pattern or syndrome, and QTc interval prolongation can occur with ROZLYTREK. Avoid coadministration of ROZLYTREK with other products that can prolong the QRS or QTc interval .
About this medicine
Entrectinib is a kinase inhibitor. The molecular formula for entrectinib is C31H34F2N6O2 and the molecular weight is 560.64 Daltons. The chemical name is N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide. The chemical structure of entrectinib is as follows:
Entrectinib is white to pale pink powder.
Capsules
ROZLYTREK (entrectinib) capsules for oral use are supplied as printed hard-shell capsules containing 100 mg (yellow opaque HPMC capsule) or 200 mg of entrectinib (orange opaque HPMC capsule). Inactive ingredients are tartaric acid, lactose anhydrous, hypromellose, crospovidone, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate.
The yellow opaque capsule shell contains hypromellose, titanium dioxide, and yellow iron oxide. The orange opaque capsule shell contains hypromellose, titanium dioxide, and FD&C yellow #6. The printing ink contains shellac, propylene glycol, strong ammonia solution, and FD&C blue #2 aluminum lake. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c7c71b0c-2549-4495-86b6-c2807fa54908. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate